IDEXX Laboratories, Inc. Share Price
Stocks
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Nasdaq
21:00:00 12/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 523.94 USD | +1.15% |
|
-0.59% | -22.55% |
| 10-12 | KeyBanc Initiates IDEXX Laboratories at Sector Weight | MT |
| 09-30 | IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI | MT |
| Market Cap | 41.28B 36.95B 34.45B 31.24B 58.93B 3,946B 59.3B 414B 162B 2,036B 155B 152B 6,552B | P/E 2026 * |
35.5x | P/E 2027 * | 31.4x |
|---|---|---|---|---|---|
| Enterprise Value | 41.64B 37.28B 34.75B 31.52B 59.45B 3,981B 59.83B 418B 163B 2,054B 156B 153B 6,611B | EV / Sales 2026 * |
8.82x | EV / Sales 2027 * | 8.01x |
| Free-Float |
72.37% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IDXX | Delayed | |
CBOE
| IDXX | Real-time | |
|
London S.E.
| 0J8P | Delayed | |
|
Tradegate
| IX1 | Real-time | |
|
Mexican S.E.
| IDXX * | End-of-day quote | |
|
Boerse Muenchen
| IX1 | Real-time | |
|
Xetra
| IX1 | Delayed | |
|
Deutsche Boerse AG
| IX1 | Delayed | |
|
Wiener Boerse
| IDXX | End-of-day quote | |
|
Börse Stuttgart
| IX1 | Delayed | |
|
Berne S.E.
| IX1 | End-of-day quote | |
|
Borsa Italiana
| 1IDXX | End-of-day quote |
Last Transcript: IDEXX Laboratories, Inc.
| 1 day | +1.15% | ||
| 1 week | -0.59% | ||
| Current month | +0.34% | ||
| 1 month | +3.81% | ||
| 3 months | -7.03% | ||
| 6 months | -6.94% | ||
| Current year | -22.55% |
| 1 week | 501.17 |  | 525.76 |
| 1 month | 501.17 | | 536.84 |
| Current year | 500.61 | | 726.41 |
| 1 year | 500.61 | | 769.98 |
| 3 years | 356.14 | | 769.98 |
| 5 years | 317.06 | | 769.98 |
| 10 years | 102.45 | | 769.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Erickson
CEO | Chief Executive Officer | 52 | 11/05/2026 |
Andrew Emerson
DFI | Director of Finance/CFO | 43 | 28/02/2025 |
Martin Smith
COO | Chief Operating Officer | 58 | 31/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 11/05/2026 | |
| Director/Board Member | 64 | 14/07/2013 | |
Daniel Junius
BRD | Director/Board Member | 73 | 10/03/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 04/09/26 | Exercice | Director | 6,609 | 0.0084% | ||
| 20/08/26 | Exercice | Chief Financial Officer | 616 | 0.0008% | ||
| 30/07/26 | Free | Director | 49 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.15% | -0.59% | -14.97% | +22.33% | 40.81B | |
| +2.23% | +1.72% | -23.20% | +12.89% | 172B | |
| +3.90% | +4.50% | -3.69% | +28.95% | 113B | |
| +1.90% | -0.92% | -22.49% | +11.33% | 106B | |
| +0.27% | +1.56% | -46.32% | -11.83% | 75.31B | |
| +0.37% | +3.22% | +2.22% | +73.30% | 61.8B | |
| +0.14% | +2.27% | +15.06% | +60.71% | 52.93B | |
| +2.80% | +4.55% | +1.25% | -26.52% | 50.05B | |
| -1.38% | -0.11% | - | - | 31.81B | |
| +2.15% | -1.13% | +31.94% | +13.82% | 31.74B | |
| Average | +1.35% | +2.04% | -6.69% | +20.55% | 73.64B | |
| Weighted average by Cap. | +1.75% | +2.17% | -12.63% | +19.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.72B 4.23B 3.94B 3.57B 6.74B 451B 6.78B 47.36B 18.54B 233B 17.74B 17.34B 750B | 5.14B 4.6B 4.29B 3.89B 7.34B 491B 7.38B 51.54B 20.18B 254B 19.3B 18.88B 816B |
| Net income | 1.18B 1.05B 983M 892M 1.68B 113B 1.69B 11.82B 4.63B 58.12B 4.43B 4.33B 187B | 1.31B 1.18B 1.1B 994M 1.87B 126B 1.89B 13.17B 5.15B 64.77B 4.93B 4.82B 208B |
| Net Debt | 368M 329M 307M 279M 525M 35.18B 529M 3.69B 1.44B 18.15B 1.38B 1.35B 58.42B | -97.34M -87.14M -81.23M -73.68M -139M -9.3B -140M -976M -382M -4.8B -366M -358M -15.45B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/10/26 | US$523.94 | +1.15% | 552,780 |
| 09/10/26 | US$518.00 | +0.95% | 466,778 |
| 08/10/26 | US$513.14 | +1.28% | 696,677 |
| 07/10/26 | US$506.67 | -1.70% | 716,449 |
| 06/10/26 | US$515.41 | -2.21% | 502,360 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IDXX Stock
Select your edition
All financial news and data tailored to specific country editions
